Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

T2 Biosystems

Status: Completed

Conditions: Bacteremia

Study type: Observational

Funder types: Industry

Identifiers

NCT01919762

PRO-00191

Details and patient eligibility

About

To assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Bacteremia Assay.

Full description

This protocol is intended for use by external sites collecting clinical research specimens for T2 Biosystems' use in developing the T2Bacterial Assay. Specimens and information on patients' medical history, blood properties, medications, and blood culture history/results are required from the T2Bacterial Assay's target patient population (i.e., candidates for blood culture). Ideally, clinical specimens for use in developing the T2Bacterial Assay will be collected from negative blood culture, positive non-bacteria blood culture and positive bacteria blood culture patients.

Enrollment: 156 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them.
• Males and females 18 - 95 years of age.

For Group A,

• Subject is confirmed to have bacteremia (gram negative rods, gram negative coccobacillus, and/or gram positive cocci) as evidenced by a positive diagnostic blood culture
• Subsequent species identification identifies the presence of one of the following 6 species of bacteria:
• Acinetobacter baumannii
• Staphylococcus aureus
• Klebsiella pneumonia
• Pseudomonas aeruginosa
• Enterococcus faecalis
• Enterococcus faecium

For Group B,

• Males and females 18 - 95 years of age.
• Subject is confirmed to not have bacteremia from the 6 bacteria species targeted by this study, as evidenced by diagnostic blood culture and subsequent species identification.

Exclusion criteria

• Use of any novel (i.e. not commercially available) drug compound within 30 days prior to the collection of T2 blood specimens.
• Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study.
• Subject has had an anti-bacterial drug administered through the same port or central line as is used to collect the clinical research specimens. A line draw cannot be used to obtain a study sample if an antibacterial agent was administered intravenously within the last 72 hours, unless the site can specifically document that a different line was used to administer the anti-bacterial agent.

Trial design

156 participants in 2 patient groups

Bacteremia Positive Patients

Description:

Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species). * Acinetobacter baumannii * Staphylococcus aureus * Klebsiella pneumonia * Pseudomonas aeruginosa * Enterococcus faecalis * Enterococcus faecium

Bacteremia Negative Patients

Description:

Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species